Experts are increasingly investigating retatrutide, a innovative medication developed by Eli Lilly, as a possible breakthrough in body loss . Unlike many existing approaches, retatrutide is a twin-action receptor targeting equally GLP-1 and GIP, hormones that impact satiety and glucose control . Pr